Search results
199 Results for 'Cancer'
- Technologies (22)
- Collaborations (1)
- Team (0)
- News (134)
- Pages (0)
- Multimedia (42)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 22
-
DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy
Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
AminoX: Making Better Protein Drugs, Quicker and Cheaper
AminoX enables protein drugs to only become active in the tumor microenvironment and not elsewhere in the body to avoid immune-related adverse effects in the body. By designing and building non-standard amino acids into strategic positions of protein drugs, AminoX provides tumor-specific, and longer-lasting target inhibition. -
ReConstruct: Vascularized tissue for breast reconstruction and augmentation
ReConstruct is a platform for growing, vascularizing, and implanting patient-derived tissues that enable safer breast reconstruction after cancer surgery. -
NodeTX: Growing lymph nodes to treat cancer
NodeTX is a novel immunotherapy that leverages the human body's innate ability to grow lymph nodes to fight tumors. -
Cellular “Backpacks” to Fight Cancer, Autoimmune Disorders, and More
Macrophages are very malleable immune cells, but that also means that they can be influenced by cancerous tumors and inflammatory processes. Our cellular "backpacks" stick to macrophages and can deliver molecules that keep them in their desired state for cell therapy and more.
Collaborations 1
i3 Center: Biomaterials to Create T Cell ImmunityNews 134
Multimedia 42
-
Video/AnimationDeep-dive Molecular Blueprinting of Therapeutic Nanostructures | Anastasia ErshovaAnastasia Ershova, a scientist at the Wyss, introduces the innovative field of bionanotechnology. In this talk from LabWeek Field Building, she explores how this cutting-edge science is revolutionizing therapeutics and diagnostics by building molecules that interact with the body in novel ways. Ershova discusses DNA nanotechnology, where DNA is used as a material to create... -
Video/AnimationAminoX: Making Better Protein Drugs, Quicker and CheaperA synthetic biology and advanced chemistry platform that efficiently incorporates non-standard amino acids by hacking the ubiquitous protein synthesis process. Credit: Wyss Institute at Harvard University -
Video/AnimationReimagine the World – Volume 4 – ReConstruct EditionDenise Skok, a two-time breast cancer survivor, Luba Perry, a scientist at the Wyss Institute, and Samuel Lin, a plastic surgeon collaborating with the Wyss Institute, are all working to reimagine a world where breast cancer patients have better reconstruction options. The ReConstruct project at the Wyss Institute uses adipose tissue assembled from a patient’s... -
Video/AnimationReimagining a World Without Breast CancerDenise Skok, a three-times cancer survivor, twice breast cancer and once skin cancer, shares the medical and emotional challenges she had to overcome to be cancer-free. Credit: Wyss Institute at Harvard University -
Video/AnimationReConstruct – 3D Bioprinted Vascularized Fat Tissues for Breast ReconstructionBreast cancer affects 15% of all women. Current options for breast reconstruction are insufficient and have poor patient outcomes. A research team at the Wyss Institute is addressing this clinical need by fabricating vascularized adipose tissue flaps for therapeutic use. Credit: Wyss Institute at Harvard University -
Video/AnimationHow can we train the immune system to fight cancer?The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient’s own immune cells on-site to kill cancer cells. This revolutionary immuno-material technology was tested in a Phase I clinical trial with promising results and is currently licensed by Novartis as an immunotherapy to treat specific tumor types. Credit: Wyss Institute at Harvard...